We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
NCI-sponsored trial for the evaluation of safety and preliminary efficacy of 3'-deoxy-3'-[18F]fluorothymidine (FLT) as a marker of proliferation in patients with recurrent gliomas: preliminary efficacy studies.
- Authors
Spence, Alexander; Muzi, Mark; Link, Jeanne; O’Sullivan, Finbarr; Eary, Janet; Hoffman, John; Shankar, Lalitha; Krohn, Kenneth; Spence, Alexander M; Link, Jeanne M; O'Sullivan, Finbarr; Eary, Janet F; Hoffman, John M; Shankar, Lalitha K; Krohn, Kenneth A
- Abstract
<bold>Purpose: </bold>3'-Deoxy-3'-[18F]fluorothymidine ([18F]FLT) is being developed for imaging cellular proliferation. The goals were to explore the capacity of FLT-positron emission tomography (PET) to distinguish between recurrence and radionecrosis in gliomas and compare the results to those obtained with 2-fluoro-2-deoxy-D: -glucose (FDG).<bold>Procedures: </bold>Fifteen patients with tumor recurrence and four with radionecrosis, determined by clinical course and magnetic resonance imaging results, were studied by dynamic [18F]FLT-PET with arterial blood sampling. A two-tissue compartment four-rate constant model was used to determine metabolic flux (K (FLT)), blood to tissue transport (K (1)), and phosphorylation (k (3)). FDG-PET scans were obtained 75-90 min postinjection.<bold>Results: </bold>K (FLT) and k (3), but not K (1) or k (3)/k (2) + k (3), reached significance for separating the recurrence from radionecrosis groups. Standardized uptake value and visual analyses of FLT or FDG images did not reach significance.<bold>Conclusions: </bold>K (FLT) (flux) appears to distinguish recurrence from radionecrosis better than other parameters, FLT and FDG semiquantitative approaches, or visual analysis of images of either tracer.
- Subjects
UNITED States; IMAGING of cancer; NATIONAL Cancer Institute (U.S.); CLINICAL trials; TUMOR markers; THYMIDINE; CELL proliferation; GLIOMAS; CANCER relapse; CANCER patients; NONPARAMETRIC statistics; BIOLOGICAL models; BIOCHEMISTRY; DEOXYRIBONUCLEOSIDES; DIFFERENTIAL diagnosis; CELL physiology; BRAIN tumors; PHENOMENOLOGY; RADIOPHARMACEUTICALS; POSITRON emission tomography; RESEARCH funding; NECROSIS
- Publication
Molecular Imaging & Biology, 2009, Vol 11, Issue 5, p343
- ISSN
1536-1632
- Publication type
journal article
- DOI
10.1007/s11307-009-0215-2